1Merz Worldwide
- 1.1Austria
- 1.2Switzerland
- 1.3Russia
- 1.4USA
- 1.5UK
- 1.6Mexiko
2Company
- 2 Company
- 2.1 Philosophy
- 2.2 Facts and Figures
- 2.3 Management Board
- 2.4 History
- 2.5 Merz Pharmaceuticals
- 2.6 Merz Consumer Care
- 2.7 Merz Dental
- 2.8 Merz Hygiene
- 2.9 Merz Pharma Group
- 2.10 Locations
3Research & Development
- 3 Research & Development
- 3.1 Clinical development program Neramexane/tinnitus
4Professionals
- 4 Professionals
5Health
6Beauty
- 6 Beauty
- 6.1 Wrinkles
- 6.2 Skin Care
- 6.3 Beauty from Within
7Press
- 7 Press
- 7.1 Press Releases
- 7.2 Photos & Logos
8Career
- 8 Career
- 8.1 Merz as an Employer
- 8.2 Job Opportunities
- 8.3 Directions
- 8.4 Contact

Welcome to Merz

Merz is an independent German pharmaceutical company with its own research and development, focused on drugs for the treatment of illnesses in the fields of neurology and psychiatry. Another field of competence is the clinical and aesthetic dermatology.

Merz counts as one of the leading organizations for Alzheimer's research worldwide. Further focal points of its research include depression, dystonia, Parkinson's disease and tinnitus.
Read more

Merz is an innovative product partner of any medical doctor specializing in aesthetic dermatology and/or plastic surgery by offering reliable products for the treatment of wrinkles and aging of the skin. In addition Merz offers products for the treatment of hair loss, scars, and acne.
Read more

The Merz Spezial® and tetesept® brands stand for innovative health, beauty and wellness products developed and distributed by Merz Consumer Care.
Read more

News

09. May 2012

Pierre Fabre and Merz in exclusive negotiations to collaborate in Aesthetics – Merz planning to take on Glytone® filler range

Pierre Fabre (France) and Merz Pharmaceuticals (Germany) today announced the kick-off of exclusive negotiations to collaborate in aesthetics. Initially, Merz intends to acquire Glytone’s® fillers, a unique family of hyaluronic acid injectables to reduce wrinkles and their accompanying dermo-cosmetic products.
15. March 2012

U.S. court restricts sale of Xeomin and dermal fillers in the U.S.

The Merz Pharma Group today confirmed that its two US subsidiaries Merz Aesthetics Inc. and Merz Pharmaceuticals LLC will for now not be allowed to market Xeomin or its dermal fillers in the U.S. market without restrictions.
26. January 2012

Change of Management at the Merz Pharma Group

A change in the Management Board of the Merz Pharma Group is taking place. Dr. Martin Zügel, Chairman of the Board, will leave the company in the course of the year to pursue other interests.
23. November 2011

Merz Pharma Group continues to flourish

Strong growth in group revenue (20.1%) and EBIT (10.6%) with research and development expenses remaining constant / Memantine builds on its leading position in the global market / Aesthetics business reinforced by focused internationalization strategy / Healthy development in non-prescribed products
03. June 2011

IQWiG recognizes the benefits of Memantine

In its recently published Rapid Report, the Institute for Quality and Efficiency in Healthcare (IQWiG) acknowledges that the anti-dementive Memantine (Axura®) is beneficial in the area of cognitive functional capacity and that there are indications of a benefit in the everyday capabilities of patients suffering from Alzheimer’s dementia.
03. June 2011

Raymond C. Stevens serves as the 21st Friedrich Merz Foundation Visiting Professor

Professor Raymond C. Stevens from the Scripps Research Institute in La Jolla (USA) was appointed as this year’s Friedrich Merz Foundation’s Visiting Professor for Pharmacology and Human Medicine at the Goethe University in Frankfurt.
01. April 2011

Positive results of the phase I study for treatment of late complications in Parkinson’s Disease

Merz Pharmaceuticals has successfully completed the first part of a phase 1 program for treatment of late complications in Parkinson`s Disease.